Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 1b/2 study of WVE-N531 in Duchenne muscular dystrophy amenable to exon 53 skipping
MOH_2023-10-30_013020Phase 2Not yet recruiting
- Sponsor
- Wave Life Sciences
- Start
- Oct 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of WVE-N531 in Duchenne muscular dystrophy (DMD), sponsored by Wave Life Sciences. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
WVE-N531
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2023-10-30_013020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-30_013020.